Go offline with the Player FM app!
Bonus Episode: Adequate mitomycin C can effectively reduce recurrence and progression in patients with IR NMIBC – the value of maintenance therapy*
Manage episode 481398043 series 3412919
This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.
Topics discussed include:
- Current confusion about the clinical heterogeneity within the intermediate-risk patient group
- The best way to select adequate intravesical therapy for this group
- The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy
*References
- Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
- European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
- Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
- Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
- Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
- Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.
200 episodes
Manage episode 481398043 series 3412919
This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.
Topics discussed include:
- Current confusion about the clinical heterogeneity within the intermediate-risk patient group
- The best way to select adequate intravesical therapy for this group
- The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy
*References
- Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
- European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
- Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
- Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
- Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
- Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.
200 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.